I Investigating the effect of sexual behaviour on oropharyngeal

2 cancer risk: a methodological assessment of Mendelian

3 randomization

- 4 Mark Gormley, BDS^{* 1,2,3}, Tom Dudding, PhD^{1,2,3}, Linda Kachuri, PhD⁴, Kimberley Burrows,
- 5 PhD^{1,3}, Amanda HW Chong, PhD^{1,3}, Richard M Martin, PhD^{1,3,5}, Steven Thomas, PhD^{2,5},
- 6 Jessica Tyrrell, PhD⁶, Andrew R Ness, PhD⁵, Paul Brennan, PhD⁷, Marcus R Munafò, PhD^{1,8},
- 7 Miranda Pring, PhD², Stefania Boccia, PhD^{9,10}, Andrew F Olshan, PhD¹¹, Brenda Diergaarde,
- 8 PhD¹², Rayjean J Hung, PhD^{13,14}, Geoffrey Liu, MD^{14,15}, Eloiza Tajara, PhD¹⁶, Patricia Severino,
- 9 PhD¹⁷, Tatiana N Toporcov¹⁸, Martin Lacko, MD PhD¹⁹, Tim Waterboer, PhD²⁰, Nicole
- 10 Brenner, PhD²⁰, George Davey Smith, FRS^{1,3}, Emma E Vincent, PhD^{1,3,21}, Rebecca C
- 11 Richmond, PhD^{1,3}

12 Affiliations

- ¹ MRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol,
 Bristol, UK.
- 15 2 Bristol Dental Hospital and School, University of Bristol, Bristol, UK.
- 16 ³ Department of Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
- 17 4 Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, USA.
- 18 5 University Hospitals Bristol and Weston NHS Foundation Trust National Institute for Health Research Bristol
- 19 Biomedical Research Centre, University of Bristol, Bristol, UK.
- 20 ⁶ University of Exeter Medical School, RILD Building, RD&E Hospital, Exeter, UK.

- 21 ⁷Genetic Epidemiology Group, World Health Organization, International Agency for Research on Cancer, Lyon,
- 22 France.
- ⁸ School of Psychological Science, Faculty of Life Sciences, University of Bristol, Bristol, UK.
- ⁹ Section of Hygiene, University Department of Life Sciences and Public Health, Università Cattolica del Sacro
- 25 Cuore, Roma, Italia.
- 26 ¹⁰ Department of Woman and Child Health and Public Health Public Health Area, Fondazione Policlinico
- 27 Universitario A. Gemelli IRCCS, Roma, Italy.
- 28 ¹¹ Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, US.
- 29 ¹² Department of Human Genetics, Graduate School of Public Health, University of Pittsburgh, and UPMC
- 30 Hillman Cancer Center, Pittsburgh, US.
- 31 ¹³ Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health
- 32 System, Toronto, Canada.
- 33
- 34 ¹⁴ Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
- 35 ¹⁵ Princess Margaret Cancer Centre, Toronto Canada
- ³⁶ ¹⁶ Department of Molecular Biology, School of Medicine of São José do Rio Preto, São Paulo, Brazil.
- 37 ¹⁷ Albert Einstein Research and Education Institute, Hospital Israelita Albert Einstein, São Paulo, Brazil.
- 38 ¹⁸ Department of Epidemiology, School of Public Health, University of São Paulo, Brazil.
- ¹⁹ Department of Otorhinolaryngology and Head and Neck Surgery, Research Institute GROW, Maastricht
- 40 University Medical Center, Maastricht, The Netherlands.
- 41 ²⁰ Infections and Cancer Epidemiology, Deutsches Krebsforschungszentrum, Heidelberg, Germany.

42 ²¹ School of Cellular and Molecular Medicine, University of Bristol, Bristol, UK.

43 * Corresponding author: mark.gormley@bristol.ac.uk

44

45 Abstract

46

47	Human papilloma virus infection is known to influence oropharyngeal cancer (OPC) risk,
48	likely via sexual transmission. However, sexual behaviour has been correlated with other
49	risk factors including smoking and alcohol, meaning independent effects are difficult to
50	establish. Here we evaluate aspects of sexual behaviour in relation to the risk of OPC (2,641
51	cases and 6,585 controls), using genetic variants associated with age at first sex (AFS) and
52	number of sexual partners (NSP) to perform Mendelian randomization (MR) analyses. While
53	univariable MR showed a causal effect of both later AFS and increasing NSP on OPC, results
54	attenuated in the multivariable models (AFS IVW OR 0.7, 95%CI 0.4, 1.2, p = 0.21; NSP IVW
55	OR 0.9, 95%CI 0.5 1.7, p = 0.76). We also found evidence for correlated pleiotropy in the
56	genetic instruments for sexual behaviour, emphasising the need for multivariable
57	approaches when performing MR of complex behavioural traits and the triangulation of
58	evidence.
59	
60	
61	
62	
63	
64	

65 Introduction

66

67	Head and neck squamous cell carcinoma (HNSCC) is a heterogeneous disease 1 , which can
68	originate from the mucosa of the oral cavity, oropharynx and larynx. Worldwide, there are
69	over half a million incident cases each year, resulting in more than 200,000 deaths annually
70	² . While using tobacco products and consuming alcohol are well-established risk factors
71	across all HNSCC subsites, oral human papilloma virus (HPV) infection has been identified as
72	another risk factor, particularly within the oropharyngeal subsite ³⁻⁶ . In developed countries
73	such as the USA, 60-70% of oropharyngeal cancer (OPC) cases are reported to be HPV-
74	positive ⁷ , compared to only around 5% of all oral cancer (OC) cases. Oncogenic HPV type-16
75	(HPV16) is the most common type found in approximately 90% of HPV-positive
76	oropharyngeal tumours ⁸⁻¹⁰ . Antibodies against HPV oncoproteins may be potential
77	biomarkers, with case-control studies demonstrating seropositivity for late (L1) and early
78	(E1, E2, E4, E6, E7) HPV16 proteins were associated with oropharyngeal cancer ¹¹⁻¹⁴ .
79	
80	HPV is thought to be sexually transmitted via oro-genital contact $^{9,15-20}$ and may enter the
81	oropharyngeal mucosa via abrasions in the reticulated tonsillar epithelium ²¹ . One large
82	pooled analysis investigating the role of sexual behaviour in HNSCC showed an increased
83	risk of OPC with having a history of six or more lifetime sexual partners (OR 1.3, 95%
84	confidence intervals (95%CI), 1.0, 1.5) and four or more oral sex partners (OR 2.3, 95%CI 1.4,
85	3.6). A positive association was observed among men who had oral sex (OR 1.6, 95%Cl 1.1,
86	2.3) and those with an earlier age at sexual debut (OR 2.4, 95%Cl 1.4, 5.1) $^{ m 15}$. Conversely,
87	there was no association reported between oral sex practice and head and neck cancer in a

89	in these findings, although 12 of these 17 studies failed to stratify by oral and oropharyngeal
90	subsite ²² . Furthermore, associations have typically been investigated using case-control
91	studies ⁵ , with self-reported sexual behaviour which may be subject to recall bias and
92	misreporting. Positive associations have also been found between sexual behaviour,
93	sexually transmitted infections and other risk factors for HNSCC, including alcohol
94	consumption, indicating the possibility of residual confounding exists ²³ .
95	
96	Mendelian randomization (MR) is an approach to causal analysis which attempts to
97	overcome shortcomings of conventional observational studies by using single nucleotide
98	polymorphisms (SNPs) which are randomly allocated at conception and known to be reliably
99	associated with modifiable risk factors of interest. These genetic instruments can be used to
100	estimate the effects of risk factors on disease outcomes, in this case sexual behaviours on
101	oropharyngeal cancer ^{24,25} , which are less prone to unidentified confounding or reverse
102	causation than conventional epidemiological analysis. Large-scale genome-wide association
103	studies (GWAS) have been performed for sexual behaviour traits, including number of
104	sexual partners (NSP) ^{26,27} and age at first sex (AFS) ²⁸ . MR makes three key assumptions in
105	that the genetic instrument (i) is robustly associated with the risk factor (i.e., 'relevance'),
106	(ii) does not share a common cause with the outcome (i.e., 'exchangeability'), and (iii)
107	affects the outcome only through the risk factor (i.e., 'exclusion restriction principle') to
108	check for genetic pleiotropy ^{24,25} .
109	
110	Here, we applied two-sample Mendelian randomization (MR) using summary-level genetic
111	data from the largest available GWAS for each sexual behaviour (sample 1) and

112 oropharyngeal cancer (sample 2). We first conducted univariable MR analysis to assess the

113	effects of NSP and AFS on oropharyngeal cancer risk. We next performed univariable MR
114	analysis to explore the effect of sexual behaviours on HPV seropositivity. Genetic proxies for
115	complex human behaviours are more likely to have broad pleiotropic effects and may
116	influence multiple upstream pathways that indirectly impact on sexual behaviour. In
117	particular, genetic variants associated with sexual behaviour may also influence the disease
118	outcome via other head and neck cancer risk factors, such as smoking and alcohol
119	consumption. For this reason we performed a number of sensitivity analyses: i) MR methods
120	to account for horizontal pleiotropy, ii) MR of sexual behaviours on positive (cervical cancer
121	and seropositivity for Chlamydia trachomatis) and negative control outcomes (lung and oral
122	cancer), iii) Causal Analysis Using Summary Effect estimates (CAUSE), to account for
123	correlated and uncorrelated horizontal pleiotropic effects ²⁹ , iv) multivariable MR analysis to
124	account for the effects of smoking, alcohol and risk tolerance.
125	
126	Despite observing an association between genetically predicted AFS and NSP and risk of
127	oropharyngeal cancer using univariable MR, further multivariable analysis indicated
128	violation of the core MR assumptions, likely due to correlated pleiotropy. This highlights the
129	importance of performing comprehensive multivariable MR and sensitivity analyses, in
130	addition to testing for correlated pleiotropy when using genetic instruments to proxy
131	complex human behaviours.
132	
133	Results

134

135 Univariable Mendelian Randomization

136	Using 139 SNPs robustly and independently associated with AFS (Supplementary Data 1),
137	there was evidence of a protective effect of later AFS on OPC (IVW OR 0.4, 95%Cl 0.3, 0.7,
138	per standard deviation (SD), p = <0.001) which was consistent across methods robust to
139	horizontal pleiotropy (MR-Egger, weighted median, and weighted mode) (Table 1 $\&$
140	Supplementary Fig.1). Using 117 SNPs (Supplementary Data 1) independently associated
141	with NSP, we found evidence to suggest an adverse effect of increased NSP on the risk of
142	OPC (IVW OR 2.2, 95%Cl 1.3, 3.8 per SD, p =<0.001). These results were consistent across the
143	other MR methods (Table 1 & Supplementary Fig.1). The protective effect of later AFS was
144	consistent across all geographical regions, with the most precise effects seen in the
145	European (IVW OR 0.4, 95%CI 0.2, 0.8, p = <0.001) and North American population (IVW OR
146	0.4, 95%CI 0.2, 0.8, p= 0.01) (Table 2). There was also suggestive evidence for an adverse
147	effect of increasing NSP across regions, with the strongest effect again in the North
148	American population (IVW OR 3.0, 95%CI 1.4, 6.5, <i>p</i> = 0.01) (Table 3).
149	

- 150 **Table 1.** Univariable Mendelian randomization results for age at first sex and number of
- 151 sexual partners on risk of oropharyngeal cancer.

Exposure/ Outcome datasets	Outcome N	Controls N	Method	Age at first s (N SNPs 13)	s ex 9)	Number of sexual (N SNPs 117	partners 7)
				OR (95%Cl)	Р	OR (95%CI)	Р
UK Biobank/ GAME-ON	2,641	6,585	IVW	0.44 (0.28, 0.70)	<0.001	2.20 (1.27, 3.81)	<0.001
UK Biobank/ GAME-ON	2,641	6,585	Weighted median	0.41 (0.23, 0.75)	<0.001	2.57 (1.24, 5.29)	0.01
UK Biobank/ GAME-ON	2,641	6,585	Weighted mode	0.23 (0.04, 1.34)	0.10	3.57 (0.58, 21.69)	0.17
UK Biobank/ GAME-ON	2,641	6,585	MR-Egger	0.21 (0.03, 1.37)	0.10	1.88 (0.12, 29.49)	0.65
	Exposure/ Outcome datasets UK Biobank/ GAME-ON UK Biobank/ GAME-ON UK Biobank/ GAME-ON	Exposure/ Outcome datasetsOutcome NUK Biobank/ GAME-ON2,641UK Biobank/ GAME-ON2,641UK Biobank/ GAME-ON2,641UK Biobank/ GAME-ON2,641UK Biobank/ GAME-ON2,641	Exposure/ Outcome datasetsOutcome NControls NUK Biobank/ GAME-ON2,6416,585UK Biobank/ GAME-ON2,6416,585UK Biobank/ GAME-ON2,6416,585UK Biobank/ GAME-ON2,6416,585UK Biobank/ GAME-ON2,6416,585UK Biobank/ GAME-ON2,6416,585	Exposure/ Outcome datasetsOutcome NControls NMethod NUK Biobank/ GAME-ON2,6416,585IVWUK Biobank/ GAME-ON2,6416,585Weighted medianUK Biobank/ GAME-ON2,6416,585Weighted medianUK Biobank/ GAME-ON2,6416,585Weighted modeUK Biobank/ 	Exposure/ Outcome NOutcome NControls NMethodAge at first st (N SNPs 13)datasetsNN(N SNPs 13)UK Biobank/ GAME-ON2,6416,585IVW0.44 (0.28, 0.70)UK Biobank/ GAME-ON2,6416,585Weighted median0.41 (0.23, 0.75) medianUK Biobank/ GAME-ON2,6416,585Weighted mode0.23 (0.04, 1.34) modeUK Biobank/ GAME-ON2,6416,585MR-Egger0.21 (0.03, 1.37) GAME-ON	Exposure/ Outcome datasets Outcome N Controls N Method N Age at first sex (N SNPs 139) UK Biobank/ GAME-ON 2,641 6,585 IVW 0.44 (0.28, 0.70) <0.001	Exposure/ Outcome datasets Outcome N Controls N Method N Age at first sex (N SNPs 139) Number of sexual (N SNPs 117) UK Biobank/ GAME-ON 2,641 6,585 IVW 0.44 (0.28, 0.70) <0.001

153

- 154 Abbreviations: OPC, oropharyngeal cancer; IVW, inverse variance weighted; OR, odds ratio; CI, confidence
- 155 intervals; P, p-value; NSP, number of sexual partners; AFS, age at first sex. AFS OR represents the exponential
- 156 change in odds of oropharyngeal squamous cell carcinoma per SD change (7.3-month delay) in age at first sex
- 157 NSP OR represents the exponential change in odds of oropharyngeal squamous cell carcinoma per SD increase
- 158 (0.94) in number of sexual partners.
- 159
- 160 **Table 2.** Inverse variance weighted univariable Mendelian randomization results for age at
- 161 first sex on risk of oropharyngeal cancer, by region.
- 162

Outcome	Region	N SNP s	Outcome N	Control N	Method	OR	CIL	CIU	P value
Oropharyngea cancer	Europe	139	1,090	2,928	Inverse variance weighted	0.36	0.17	0.78	<0.001
Oropharyngea cancer	North America	139	1,119	2,329	Inverse variance weighted	0.41	0.20	0.83	0.01
Oropharyngea cancer	South America	139	205	727	Inverse variance weighted	0.38	0.07	1.95	0.24

163

164 Abbreviations: SE, standard error; OR, odds ratio; CIL, lower confidence interval; CIU, upper confidence

165 interval; P, p-value. OR represents the exponential change in odds of oropharyngeal squamous cell carcinoma

166 per SD change (7.3-month delay) in age at first sex.

167

168 **Table 3.** Inverse variance weighted univariable Mendelian randomization results for number

169 of sexual partners on risk of oropharyngeal cancer, by region.

170

Outcome	Region	N SNPs	Outcome N	Control N	Method	OR	CIL	CIU	P value
Oropharyngeal cancer	Europe	117	1,090	2,928	Inverse variance weighted	1.48	0.66	3.33	0.35
Oropharyngeal cancer	North America	117	1,119	2,329	Inverse variance weighted	2.99	1.37	6.51	0.01
Oropharyngeal cancer	South America	117	205	727	Inverse variance weighted	2.68	0.56	12.75	0.22

- 172 Abbreviations: SE, standard error; OR, odds ratio; CIL, lower confidence interval; CIU, upper confidence
- 173 interval; P, p-value. OR represents the exponential change in odds of oropharyngeal squamous cell carcinoma
- 174 per SD increase (0.94) in number of sexual partners.
- 175
- 176 *MR* for effect of sexual behaviours on HPV seropositivity
- 177 Using the NSP and AFS instruments, we next evaluated the effect of sexual behaviour on the

178 risk of HPV seropositivity in healthy individuals, using a GWAS of serological measures in UK

- 179 Biobank. There appeared to be some evidence for a protective effect of later AFS (IVW OR
- 180 0.5, 95%Cl 0.2, 1.0, *p*=0.05) on HPV16 L1 seropositivity (**Table 4 & Supplementary Table 1**).
- 181 However, there was limited evidence for a similar protective effect on HPV18 L1, HPV16 E6
- 182 or E7 seropositivity. While there was some evidence that increasing NSP also increased the
- 183 likelihood of HPV16 E6 seropositivity (IVW OR 5.4, 95%Cl 1.0, 28.3, *p*=0.05), this was
- 184 inconsistent among the other tested HPV antibodies (Table 4 & Supplementary Table 2).
- 185
- 186 **Table 4.** Inverse variance weighted univariable Mendelian randomization results of age at
- 187 first sex with HPV seropositivity.

Exposure	Outcome (serostatus)	N seropositive	N seronegative	Method	OR	CIL	CIU	P value
Age at first sex	HPV16 L1	344	7580	Inverse variance weighted	0.47	0.21	1.01	0.05
	HPV16 E6	133	7791	Inverse variance weighted	1.35	0.38	4.74	0.64
	HPV16 E7	256	7668	Inverse variance weighted	1.51	0.62	3.66	0.36
	HPV18 L1	191	7733	Inverse variance weighted	0.76	0.28	2.10	0.60
Number of sexual	HPV16 L1	344	7580	Inverse variance weighted	2.07	0.74	5.83	0.17
partners	HPV16 E6	133	7791	Inverse variance weighted	5.39	1.03	28.30	0.05
	HPV16 E7	256	7668	Inverse variance weighted	0.89	0.28	28.00	0.84
	HPV18 L1	191	7733	Inverse variance weighted	0.47	0.13	1.73	0.25

Abbreviations: SE, standard error; OR, odds ratio; CIL, lower confidence interval; CIU, upper confidence

interval; P, p-value. Age at first sex OR represents the exponential change in odds of HPV seropositivity per SD

1	8	8
- 1	.,	ι,

189

190

191

192	change (7.3-month delay) in age at first sex. Number of sexual partners OR represents the exponential change
193	in odds of HPV marker seropositivity per SD increase (0.94) in number of sexual partners.
194	
195	Sensitivity analyses
196	There was limited evidence of weak instrument bias (F-statistic >10) and the proportion of
197	variance in the phenotype (R^2) explained by the genetic instruments ranged from 1 - 2%
198	(Supplementary Table 3). There was limited evidence for heterogeneity in the SNP effect
199	estimates for the AFS instrument (QIVW 159.4, p = 0.10; Q MR-Egger 158.6, p = 0.10), but
200	clear evidence of heterogeneity in the NSP instrument (QIVW 155.6, <i>p</i> = 0.007; Q MR-Egger
201	155.6, <i>p</i> = 0.006) (Supplementary Table 4). MR-Egger intercepts were not indicative of
202	directional pleiotropy (Supplementary Table 5) but there were outliers present on visual
203	inspection in both scatter and leave-one-out plots (Supplementary Figs.2 & 3). MR-PRESSO
204	identified 8 outliers for AFS and 7 outliers for NSP, which when corrected for, yielded effects
205	consistent with univariable MR for both instruments (Supplementary Tables 6-8). There was
206	evidence of violation of the NOME assumption for both AFS and NSP genetic instruments
207	(i.e., I ² statistic <0.90) (Supplementary Table 9), so MR-Egger was performed with SIMEX
208	correction. The effects were consistent with previous MR-Egger results for AFS, but there
209	was significant attenuation of the NSP effect on oropharyngeal cancer (SIMEX corrected MR-
210	Egger OR 3.6, 0.4, 32.1, p= 0.25) (Supplementary Table 10). These estimates should
211	however be interpreted with caution, given evidence of high dilution in the SNP-exposure
212	effects ³⁰ .

213

214 Positive and negative control analyses

- 215 Univariable MR analysis conducted within UK Biobank found a protective effect for later AFS
- 216 on cervical cancer, which is known to be another HPV-driven cancer type (IVW OR 0.4,
- 217 95%Cl 0.3, 0.7, p= <0.001) (Supplementary Table 11). A similar effect was found when
- assessing the effect of AFS on C. trachomatis seropositivity based on pGP3 antigen, another
- 219 positive control (IVW OR 0.4, 95%CI 0.3, 0.6, *p*= <0.001) (**Supplementary Table 11**). There
- 220 was also evidence for an adverse effect of increasing NSP on cervical cancer risk (IVW OR
- 1.9, 95CI% 1.0, 3.9, p= 0.06) and a positive association between NSP and C. trachomatis

222 serostatus (IVW OR 2.4, 95%Cl 1.4, 4.1, *p*= <0.001) (**Supplementary Table 12**).

223

Using lung cancer as a negative control, in univariable MR there was a strong protective

225 effect of AFS (IVW OR 0.1 95%CI, 0.1, 0.3 *p*= <0.001) (**Supplementary Table 11**) and an

- adverse effect of increasing NSP (IVW OR 7.1 95%Cl, 2.4, 21.6 *p*= <0.001) (**Supplementary**
- 227 Table 12), indicating violation of the MR assumptions. A protective effect was also observed

in relation to AFS with oral cancer, another negative control (IVW OR 0.6, 95%CI 0.4, 1.0, p=

229 0.03) (Supplementary Table 11); however, there was no effect for NSP on oral cancer (IVW

230 OR 1.2, 95%CI 0.7, 2.0, *p*= 0.47) (Supplementary Table 12).

231

232 While there was no strong evidence for directional pleiotropy (**Supplementary Table 13**),

there was some evidence of heterogeneity (Supplementary Table 14) for both AFS and NSP

- in the lung and oral cancer analyses, suggesting that pleiotropy may be present ³¹. While
- scatter and leave-one-out plots showed no obvious outliers (Supplementary Figs.4-7), MR-
- 236 PRESSO identified outliers for AFS and for NSP across all positive and negative controls.

- 237 When corrected for outliers, the lung cancer results remained consistent with the
- 238 univariable MR, suggesting further violation of the MR assumptions for the AFS and NSP
- 239 instruments (Supplementary Tables 15-17).
- 240
- 241 Investigating correlated pleiotropy using CAUSE
- 242 We used GWAS summary statistics to evaluate evidence for an effect of AFS and NSP on
- oropharyngeal cancer, using the Causal Analysis using Summary Effect estimates (CAUSE)
- 244 method to account for correlated pleiotropy ³². For AFS, CAUSE suggested there was
- relatively similar evidence for sharing (correlated pleiotropy) (p= 0.02) and causal models
- 246 (p= 0.05) compared to the null (no effect) model (Supplementary Table 18 &
- 247 Supplementary Fig.8). Comparing both shared and causal models, there was limited
- evidence that the causal model fit the data better than the sharing model (p= 0.44),
- indicating that correlated pleiotropy could not be discounted. When investigating the causal
- effect of NSP on oropharyngeal cancer, neither shared (p= 0.30) nor causal (p= 0.27) models
- appeared to fit in comparison to the null model, providing limited evidence for a causal

252 effect of NSP (Supplementary Table 19 & Supplementary Fig.9).

253

254 Multivariable MR

- 255 In total there were 21 overlapping SNPs identified between genetic instruments
- 256 (Supplementary Table 20) and LD score regression highlighted strong genetic correlation
- between the traits (rg = |0.20-0.63|) Supplementary Table 21 & Supplementary Fig.10).
- 258 Multivariable MR analysis was therefore carried out to investigate the direct causal effect of
- AFS and NSP on oropharyngeal cancer after accounting for the other sexual behaviour,
- smoking, alcohol, and risk tolerance. While the effect of NSP diminished (IVW OR 0.8, 95%CI

261	0.3, 2.0, <i>p</i> = 0.60), the AFS effect remained (IVW OR 0.4, 95%CI 0.2, 0.9, <i>p</i> = 0.04), after
262	accounting for the other sexual behaviour in multivariable MR (Tables 5 & 6; Fig.1). When
263	accounting for smoking and risk tolerance, the effect of AFS remained consistent within the
264	oropharyngeal subsite (Table 5 & Fig.2). However, there was attenuation of the effect for
265	AFS when controlling for drinks per week (IVW OR 0.7, 95%CI 0.4, 1.2, p = 0.21). The effect of
266	NSP on oropharyngeal cancer attenuated when accounting for lifetime smoking (IVW OR
267	0.9, 95%Cl 0.5 1.72, p= 0.76), alcohol consumption (IVW OR 1.5, 95%Cl 0.8, 2.8, p= 0.27) and
268	risk tolerance (IVW OR 2.0, 95%CI 0.9, 4.4, p= 0.07) (Table 6 & Fig.3) These results suggest
269	the NSP and AFS instruments may include pleiotropic variants related to smoking and
270	drinking behaviours. Some of the multivariable models including smoking initiation and
271	drinks per week showed high levels of heterogeneity and therefore further risk of invalid
272	instruments (Tables 5 $\&$ 6). However, the MR-Egger intercepts in the multivariable analyses
273	were consistent with the null, indicative of no further directional pleiotropy (Supplementary
274	Table 22) and the effects estimated were also consistent across both IVW and MR-Egger
274 275	Table 22) and the effects estimated were also consistent across both IVW and MR-Egger models (Tables 5 & 6).
274 275 276	Table 22) and the effects estimated were also consistent across both IVW and MR-Egger models (Tables 5 & 6).
 274 275 276 277 	Table 22) and the effects estimated were also consistent across both IVW and MR-Egger models (Tables 5 & 6).
274275276277278	Table 22) and the effects estimated were also consistent across both IVW and MR-Egger models (Tables 5 & 6).
 274 275 276 277 278 279 	Table 22) and the effects estimated were also consistent across both IVW and MR-Egger models (Tables 5 & 6).
 274 275 276 277 278 279 280 	Table 22) and the effects estimated were also consistent across both IVW and MR-Egger models (Tables 5 & 6).
 274 275 276 277 278 279 280 281 	Table 22) and the effects estimated were also consistent across both IVW and MR-Egger models (Tables 5 & 6).
 274 275 276 277 278 279 280 281 282 	Table 22) and the effects estimated were also consistent across both IVW and MR-Egger models (Tables 5 & 6).
 274 275 276 277 278 279 280 281 282 283 	Table 22) and the effects estimated were also consistent across both IVW and MR-Egger models (Tables 5 & 6).



286 Fig.1 Forest plot comparing univariable and multivariable Mendelian randomization effects





301

302 Effect estimates are reported on the log odds scale with 95% confidence intervals. Age at first sex point

303 estimate represents the exponential change in odds of oropharyngeal squamous cell carcinoma per SD change

304 (7.3-month delay) in age at first sex. Number of sexual partners point estimate represents the exponential

305 change in odds of oropharyngeal squamous cell carcinoma per SD increase (0.94) in number of sexual partners.

306

307

Table 5. Multivariable Mendelian randomization for age at first sex with risk of

310 oropharyngeal cancer.

Exposure	Exposure dataset	N SNPs	F-stat	Q-stat	P-value for instrument validity	Method	AFS OR	95% Cl	P
Number of Sexual partners	UK Biobank ³³	152	7.81	214.14	3.77x10 ⁻⁴	IVW	0.42	0.19, 0.94	0.04
						MR Egger	0.24	0.06, 1.01	0.05
Comprehensive Smoking Index	UK Biobank ³⁴	174	8.87	191.26	0.14	IVW	0.48	0.25, 0.95	0.03
						MR-Egger	0.71	0.23, 2.19	0.56
Smoking initiation	G SCA N ³⁵	215	6.43	250.58	0.04	IVW	0.42	0.21, 0.83	0.01
						MR-Egger	0.61	0.21, 1.74	0.35
Drinks per week	G SCA N ³⁵	147	28.88	164.77	0.11	IVW	0.72	0.43, 1.20	0.21
						MR-Egger	0.43	0.14	1.28
Risk tolerance	UK Biobank ²⁶	160	13.68	171.18	0.21	IVW	0.53	0.30, 0.93	0.03
12						MR-Egger	0.24	0.08. 0.72	0.01

313 Abbreviations: IVW, inverse variance weighted; AFS, age at first sex; OR, odds ratio; CI, confidence intervals; P,

p-value; Q-stat, Cochran's Q statistic; F-stat, conditional F-statistic. AFS OR represents the odds ratio of

315 oropharyngeal squamous cell carcinoma per SD change (7.3-month delay) in age at first sex.

320 **Table 6.** Multivariable Mendelian randomization for number of sexual partners with risk of

321 oropharyngeal cancer.

322

Exposure	Exposure dataset	N SNPs	F-stat	Q-stat	P-value for instrument validity	Method	NSP OR	95% Cl	Р
Age at first sex	UK Biobank ³³	152	7.26	214.14	3.77x10 ⁻⁴	IVW	0.79	0.32, 1.96	0.60
						MR Egger	0.97	0.35, 2.65	0.95
Comprehensive Smoking Index	UK Biobank ³⁴	157	12.18	168.74	0.20	IVW	0.91	0.48, 1.72	0.76
						MR-Egger	0.86	0.39, 1.88	0.70
Smoking initiation	GSCAN ³⁵	195	7.35	204.67	0.25	IVW	1.51	0.77, 2.97	0.23
						MR-Egger	1.66	0.66, 4.15	0.28
Drinks per week	GSCAN ³⁵	117	22.7	151.65	0.011	IVW	1.45	0.75, 2.79	0.27
						MR-Egger	1.61	0.76, 3.41	0.21
Risk tolerance	UK Biobank ²⁶	125	7.06	145.56	0.072	IVW	2.04	0.93, 4.44	0.07
						MR-Egger	2.12	0.66, 6.83	0.21

323

324 Abbreviations: IVW, inverse variance weighted; NSP, number of sexual partners; OR, odds ratio; CI, confidence

325 intervals; *P, p-value*; Q-stat, Cochran's Q statistic; F-stat, conditional F-statistic. NSP OR represents the odds

326 ratio of oropharyngeal squamous cell carcinoma per SD increase (0.94) in number of sexual partners.

327

- 329
- 330331
- ----
- 332

- 333 Fig.2 Forest plot showing multivariable Mendelian randomization results for age at first sex
- 334 single nucleotide polymorphisms with risk of oropharyngeal cancer.
- 335



- 368
- 369
- 370
 371
- 372 Effect estimates on oropharyngeal cancer risk are reported on the log odds scale with 95% confidence

374 change (7.3-month delay) in age at first sex. Comprehensive smoking index (dark orange), smoking initiation

375 (light orange), alcoholic drinks per week (yellow), risk tolerance (blue).

- 376
- 377
- 378

intervals. Age at first sex OR represents the change in odds of oropharyngeal squamous cell carcinoma per SD

379 Fig.3 Forest plot showing multivariable Mendelian randomization results for number of

- 380 sexual partners single nucleotide polymorphisms with risk of oropharyngeal cancer.
- 381
- 382



- 417
- 418
- 419

420	In additional multivariable MR analysis of AFS and NSP on lung cancer, effects for both
421	instruments were attenuated once smoking was included in the model. With AFS, this was
422	clearly seen when controlling for smoking initiation (IVW OR 1.1, 95%Cl 0.8, 1.6, p = 0.57)
423	and a change in direction of the effect of AFS was evident when controlling for the
424	comprehensive smoking index (IVW OR 2.0, 95%CI 1.3, 3.0, <i>p</i> <0.001) (Supplementary Table
425	23 & Supplementary Fig.11). Similarly, there was limited evidence for an effect of NSP on
426	lung cancer when controlling for the comprehensive smoking index (IVW OR 0.7, 95%CI 0.4,
427	1.1, p = 0.09). The MR-Egger intercept deviated from the null in the multivariable models
428	including smoking, suggestive of further directional pleiotropy in this analysis
429	(Supplementary Table 24).
430	
431	Discussion
432	
433	In this study we applied Mendelian randomization to evaluate the effects of both later age
434	at first sex and increased number of sexual partners on the risk of oropharyngeal cancer. We
435	observed convergence between genetic pathways influencing sexual behaviors and
436	susceptibility to oropharyngeal cancer, which may be partly mediated by HPV infection,
437	however, we also uncovered complex correlated pleiotropy with other putative risk factors.
438	Univariable MR results suggested a protective effect of later age at first sex and an adverse
439	effect of increased number of sexual partners. However, these effects attenuated in the
440	multivariable MR analyses that controlled for smoking behaviour and alcohol consumption.
111	
441	While there was suggestive evidence for an effect of sexual behaviours on some HPV16
442	While there was suggestive evidence for an effect of sexual behaviours on some HPV16 serology measures and in cervical cancer (supportive of a causal mechanism via HPV

oral cancer) indicating potential violation of the MR assumptions. Furthermore, CAUSE
provided less support for a causal effect of AFS and NSP on oropharyngeal cancer risk,
highlighting the risk of correlated pleiotropy in the genetic instruments for these complex
behavioural traits.

448

449 Sexual behaviours and HPV transmission

450 Over 90% of HPV positive OPC is caused by the high-risk genotype 16, with almost all oral infections thought to be sexually acquired ³⁶. HPV is a small non-enveloped DNA virus, with 451 452 its genome encoding for both early oncoproteins E6/E7 and the late capsid proteins such as 453 L1. The overexpression of these oncogenes is thought to stimulate proliferation and lateral 454 expansion of epithelial basal cells, progressing to a malignant phenotype. HPV E6 forms a 455 complex which leads to rapid degradation of tumour suppressor protein p53, resulting in 456 deregulation of cell cycle checkpoints. E7 binds to a complex which ubiquitinates another 457 tumour suppressor protein, retinoblastoma (pRb), again resulting in uncontrolled G1/S phase of the cell cycle ³⁷. While the transmission of HPV via sexual intercourse is well known 458 459 and HPV in turn a major risk factor for cervical malignancies, the role of HPV in oropharyngeal cancer risk has only been acknowledged in recent decades⁸. Among OPC 460 461 cases, HPV16 E6 serology is a good biomarker (~99% specificity, >90% sensitivity) and therefore both E6 and E7 are highly associated with this disease ³⁸. However, when studying 462 463 these antibodies in the general population, E6 seroprevalence appears to be very low (0.5-464 1%), but in comparison with low incidence rates of HPV-positive OPC this figure is still high, 465 suggesting that not all individuals in the general population who have HPV16 E6 seropositivity will develop an oropharyngeal tumour or other HPV-associated cancer ³⁸. 466 467 Consequently, we performed this analysis in UK Biobank and observed a strong and

468	consistent association with sexual behavior. In our univariable MR analysis, the effects of
469	AFS and NSP instruments on risk of HPV16 and HPV18 seropositivity were not consistent,
470	compared with recent observational studies which demonstrate an association between
471	serology markers and sexual behaviour responses in UK Biobank ³⁸ . This could be as a result
472	of the small number of seropositive HPV16 (n= <450) and HPV18 (n= 265) cases within the
473	UK Biobank pilot study used in our genetic analysis or that results from genetic proxies and
474	questionnaire data are not directly comparable ³⁹ . Using serology measures to predict HPV
475	seropositivity or a HPV-positive OPC diagnosis is not straightforward, often requiring the use
476	of multiple markers simultaneously 40 . Going forward, more reliable tests may emerge which
477	could improve our prediction of both the infection and disease.
478	
479	Regional differences in sexual behaviour and HPV prevalence
480	Although the incidence of OPC in South America is similar to that in Western Europe and

481 North America, the prevalence of HPV16 is reportedly low ⁴¹. Latin America has an

482 estimated overall HPV-positive head and neck cancer prevalence of between 3 – 4%,

483 compared with 25% in European and North American populations ⁴¹⁻⁴³. This could partly be

484 explained by differences in data collection and methods used to detect HPV. Despite Latin

485 American countries having an average age of sexual debut between 18-19 years old ⁴⁴, the

486 International Head and Neck Cancer Epidemiology (INHANCE) Consortium found that these

487 countries reported higher mean numbers of sexual partners (e.g., Brazil n=22), compared

488 with North American (e.g., USA, Atlanta n=10) or European (e.g., Warsaw n= 15) populations

489 ¹⁵. Stratifying by region in our univariable MR analysis, we found a consistent protective

490 effect for AFS and similarly, a consistent increased risk effect for NSP across all three regions

491 (Europe, North America, and South America), with evidence for the most precise effects in

492	the North American population. In the largest pooled analysis, authors also report possible
493	recall or reporting biases, given that some of the sexual behaviour interviews were carried
494	out with family members nearby, in addition to small sample sizes (<150 cases) ¹⁵ which may
495	have affected their results.

496

497 Confounding by other risk factors

498 While transmission of HPV to the upper aerodigestive tract is thought to be through oral sexual contact ^{9,15-20}, a more recent meta-analysis reported no association between oral sex 499 practices and head and neck cancer risk ²². This could be explained by the inclusion of older 500 studies ²², which may not have captured the more recent rise in number of HPV-positive 501 502 OPC cases which has been described by some as an 'epidemic' and predicted to overtake oral cancer within the next decade ⁴⁵. However, a study in the UK found that there was no 503 504 change in the proportion of HPV-attributable cases from 2002-2011, although the incidence 505 of OPC doubled over the same time period and national surveys have not described an increase in oral sex behaviour ^{1,46}. In one multi-national study of 1,626 men aged 18–73 506 507 years with 4-year follow-up, no association was detected between oral sexual behaviours 508 and incident HPV infection, but oral oncogenic HPV was found to be more prevalent in current smokers compared with non-smokers ⁴⁷. Furthermore, tobacco exposure induces 509 proinflammatory and immunosuppressive effects, which could potentially increase the 510 likelihood of HPV infection and persistence ^{48,49}. Since risk factors such as smoking and 511 512 alcohol consumption are strongly associated with sexual behaviour and are well established 513 in the aetiology of HNSCC, this may confound the relationship between sexual behaviours with HPV transmission and similarly oropharyngeal cancer in observational studies ^{50,51}. 514

515

516	Although Mendelian randomization analysis minimises the likelihood of confounding, since
517	germline genetic variants should not theoretically be influenced by subsequent
518	environmental confounders, pleiotropy is a major concern whereby genetic variants
519	associated with the exposure (sexual behaviours) are related to the outcome
520	(oropharyngeal cancer) through alternative, independent biological pathways. We used a
521	series of analyses to evaluate the potential for pleiotropy. We first performed several
522	methods (MR-Egger 52 , weighted median 53 and weighted mode 54) which allow for the
523	existence of horizontal pleiotropy and correct for this. We also identified and corrected for
524	outlier SNPs most likely to exhibit pleiotropic effects. In univariable MR analyses, estimates
525	were consistent with an effect of AFS and NSP on oropharyngeal cancer risk. However, in
526	further MR analysis taking lung cancer as a negative control, we observed the same
527	direction of effect for AFS and NSP which we did not expect, since there is no plausible
528	biological mechanism directly linking sexual behaviour with lung cancer risk. Evidence of an
529	effect here indicates potential violation of the MR assumptions.
530	
531	Strong genetic correlation between sexual behaviours and other risk factors such as
532	smoking, alcohol and general risk tolerance were found using LD score regression. The
533	genetic instruments used in MR may therefore comprise variants which primarily influence
534	other risk factors, which could induce correlated pleiotropy (Fig.4). We conducted two
535	subsequent analyses to evaluate this. The CAUSE approach provided limited evidence for
536	any effect of NSP on oropharyngeal cancer and was unable to distinguish an effect of AFS
537	from the situation of correlated pleiotropy. We also performed multivariable MR to control
538	for alcohol, smoking and risk tolerance, so as to determine the direct causal effect of sexual
539	behaviours on oropharyngeal cancer. Effect estimates attenuated when alcohol and

540 smoking were taken into account in the multivariable MR models, again highlighting the role 541 of potential pleiotropy in the genetic instruments for sexual behaviour.

542

543 Strengths and limitations

544	MR was employed in this study in an attempt to overcome the drawbacks of conventional
545	epidemiological studies. However, MR makes various assumptions which if violated may
546	generate spurious conclusions. For example, sexual behaviours are difficult to instrument
547	genetically due to measurement error (e.g., as a result of reporting bias) and because they
548	are time-varying as well as context and culture-dependent. This could hamper the detection
549	of genetic associations related to these traits which has implications for genetic instrument
550	strength (the first assumption of MR), given the low percentage of variation explained (R^2),
551	as well as potential violation of the no measurement error (NOME) assumption, with

552 relatively low I² values.

553

554 Additionally, the available genetic instruments are not specifically for oral sex, which is the 555 conceptually relevant exposure and mode of HPV transmission. However, other sexual 556 behaviours are likely to be correlated and developing genetic instruments for specific sexual 557 activities poses some methodological and ethical challenges. While the random inheritance 558 of genetic variants from parents to offspring means genotypes are typically much less 559 associated with many potential confounders than directly measured exposures (the second 560 MR assumption), an obvious violation of this is created due to population stratification 561 which can introduce confounding of genotype-outcome associations. Although the GWAS 562 for both NSP and AFS were adjusted for genetic principal components, given that sexual 563 behaviours are strongly socially patterned, residual population structure may reintroduce

564	confounding into MR analysis. Although a rare outcome, there is potential sample overlap
565	present as head and neck cancer cases were not excluded from previously published AFS or
566	NSP GWAS, however recent studies suggest the incurred bias is much less substantial than
567	that due to weak instruments, or overestimation of the SNP-trait effect ^{55,56} .
568	
569	The third major assumption of MR is the exclusion restriction principle (i.e., that the genetic
570	variant affects the outcome exclusively through its effect on the exposure). We performed a
571	series of comprehensive sensitivity analyses to evaluate potential violation of this
572	assumption. While several pleiotropy-robust (MR-Egger, weighted median, and weighted
573	mode) and outlier exclusion methods provided limited evidence for violation of this
574	assumption, the results of the lung cancer negative control analysis, CAUSE method and
575	multivariable MR all suggested violation of the exclusion restriction assumption in the
576	univariable MR of sexual behaviours on oropharyngeal cancer risk. When multiple sources
577	of evidence provide conflicting estimates, it is necessary to appraise the relative biases of
578	the approaches in order to best "triangulate" evidence ^{57,58} . In this instance, it is possible
579	that the primary phenotype for the genetic variants used to instrument the sexual
580	behaviours has been mis-specified. For example, the genetic variants may be primarily
581	associated with other traits (e.g., risk taking) and indirectly to sexual behaviours via the
582	primary traits. Similarly, sexual behaviour instruments may be associated with traits which
583	don't have a direct negative connotation. In this instance, the Instrument Strength
584	independent of Direct Effect (InSIDE) assumption of approaches such as MR-Egger is likely to
585	be violated, whereas the CAUSE is less vulnerable to environmental confounders that are
586	correlated with genetic variants than the other pleiotropy-robust methods. Multivariable
587	MR was also used to directly model the potential indirect effects of the genetic variants via

589	
	CAUSE method. Finally, we could not distinguish between HPV positive and negative
590	oropharyngeal tumours in the GAME-ON summary data, which would require further
591	analysis at an independent level or a GWAS of oropharyngeal cancer stratified by HPV
592	status. The GWAS-by-subtraction approach ⁵⁹ could be useful to account for latent factors of
593	other behavioral traits to identify more specific genetic instruments for sexual behaviour, if
594	valid instruments for these traits exist. More serological data may become available in the
595	UK Biobank and other clinical genetic studies, which could enhance power to evaluate
596	potential the extent to which any effect of sexual behaviour on cancer risk is mediated by
597	HPV.
598	
599	Conclusions
600	In conclusion, this study used a comprehensive series of MR analyses to investigate sexual
601	behaviours in relation to oropharyngeal cancer. We initially observed an association
602	between genetically predicted AFS and NSP and risk of oropharyngeal cancer using
602 603	between genetically predicted AFS and NSP and risk of oropharyngeal cancer using univariable MR. Despite using genetic variants strongly related to these traits in large-scale
602 603 604	between genetically predicted AFS and NSP and risk of oropharyngeal cancer using univariable MR. Despite using genetic variants strongly related to these traits in large-scale GWAS, further multivariate methods indicated violation of the core MR assumptions, likely
602 603 604 605	between genetically predicted AFS and NSP and risk of oropharyngeal cancer using univariable MR. Despite using genetic variants strongly related to these traits in large-scale GWAS, further multivariate methods indicated violation of the core MR assumptions, likely due to correlated pleiotropy. Effect estimates attenuated when alcohol and smoking were
602 603 604 605 606	between genetically predicted AFS and NSP and risk of oropharyngeal cancer using univariable MR. Despite using genetic variants strongly related to these traits in large-scale GWAS, further multivariate methods indicated violation of the core MR assumptions, likely due to correlated pleiotropy. Effect estimates attenuated when alcohol and smoking were taken into account in the multivariable MR models, highlighting the importance of
602 603 604 605 606 607	between genetically predicted AFS and NSP and risk of oropharyngeal cancer using univariable MR. Despite using genetic variants strongly related to these traits in large-scale GWAS, further multivariate methods indicated violation of the core MR assumptions, likely due to correlated pleiotropy. Effect estimates attenuated when alcohol and smoking were taken into account in the multivariable MR models, highlighting the importance of performing these further analyses, particularly when using genetic instruments which proxy
602 603 604 605 606 607 608	between genetically predicted AFS and NSP and risk of oropharyngeal cancer using univariable MR. Despite using genetic variants strongly related to these traits in large-scale GWAS, further multivariate methods indicated violation of the core MR assumptions, likely due to correlated pleiotropy. Effect estimates attenuated when alcohol and smoking were taken into account in the multivariable MR models, highlighting the importance of performing these further analyses, particularly when using genetic instruments which proxy complex behavioural traits.
 602 603 604 605 606 607 608 609 	between genetically predicted AFS and NSP and risk of oropharyngeal cancer using univariable MR. Despite using genetic variants strongly related to these traits in large-scale GWAS, further multivariate methods indicated violation of the core MR assumptions, likely due to correlated pleiotropy. Effect estimates attenuated when alcohol and smoking were taken into account in the multivariable MR models, highlighting the importance of performing these further analyses, particularly when using genetic instruments which proxy complex behavioural traits.

612 Methods

613

614 Summary-level data for sexual behaviours

015	Summary statistics for AFS were obtained from a GWAS conducted in the UK Biobank
616	(n=397,338) ²⁸ . AFS was treated as a continuous variable, with individuals considered as
617	eligible if they had given a valid answer to the question "What was your age when you first
618	had sexual intercourse? (Sexual intercourse includes vaginal, oral or anal intercourse)" and
619	ages <12 years old were excluded. Since AFS had a non-normal distribution, a within-sex
620	inverse rank normal transformation was applied ²⁸ . Where possible the full 272 SNP AFS
621	instrument was used, except in the primary analysis of OPC, whereby only 139 SNPs could
622	be extracted from head and neck cancer data. We obtained summary statistics for the NSP
623	instrument (117 SNPs) from a GWAS conducted in UK Biobank ²⁶ (n=2370,711). NSP was
624	treated as a continuous variable based on responses to the question: "About how many
625	sexual partners have you had in your lifetime?". Respondents who reported >99 lifetime
626	sexual partners were asked to confirm their responses and a value of zero was assigned to
627	participants who reported having never had sex, which was normalised separately for both
628	males and females with an inverse rank normal transformation ²⁶ . Both AFS and NSP GWAS
629	adjusted for the top 10 principal components (accounting for population stratification), sex,
630	and birth year. For AFS, those participants with family data were controlled with non-
631	independence of family members or else one family member was included in the analysis ²⁸
632	
633	Summary-level data for oropharyngeal cancer

634 The largest available GWAS for oropharyngeal cancer was performed on 2,641 OPC cases
635 and 6,585 matched controls from 12 studies which were part of the Genetic Associations

636	and Mechanisms in Oncology (GAME-ON) Network ⁶⁰ . Cancer cases comprised the following
637	ICD-10 codes: oropharynx (C01.9, C02.4 and C09.0–C10.9). Stratification was conducted by
638	geographical region to evaluate potential heterogeneity in any effects given potential
639	differences in the distribution of genetic variants for specific traits within populations. As
640	GAME-ON included participants from Europe (45.3%), North America (43.9%) and South
641	America (10.8%), this study was restricted to individuals of predominantly European
642	ancestry to avoid the effect of population structure. Details of the studies included as well
643	as the genotyping and imputation performed have been described previously 60,61 .
644	
645	Univariable Mendelian randomization
646	To assess effects of NSP and AFS, we used SNPs which reached genome-wide significance (p
647	$<5x10^{-8}$) in the respective GWAS and for which pairwise r ² <0.1 (with 250kb linkage
648	disequilibrium (LD) windows), ensuring only independent SNPs were selected into the
649	instrument. Two-sample MR analyses were conducted using the "TwoSampleMR" package
650	(version 0.5.5) in R (version 4.0.2) to extract the SNPs instrumenting the risk factor from the
651	oropharyngeal cancer GWAS. Harmonization of the direction of effects between exposure
652	and outcome associations was performed and palindromic SNPs were aligned when minor
653	allele frequencies (MAFs) were less than 0.3 or were otherwise excluded. SNP specific Wald
654	estimates were calculated (SNP-outcome estimate divided by SNP-exposure estimate) and
655	an inverse variance weighted (IVW) method applied to meta-analyse these in order to
656	obtain an effect estimate of the risk factor on oropharyngeal cancer risk.
657	

658 MR for sexual behaviours on HPV and C. trachomatis seropositivity

659	Where there was evidence for an effect of sexual behaviour on oropharyngeal cancer risk,
660	we also aimed to confirm the suspected aetiological link via HPV, by investigating the effects
661	of NSP and AFS on a range of seropositivity measures against HPV16 L1, E6, E7 and HPV18
662	L1 proteins. Here, seropositivity suggests previous HPV exposure, which can be a predictor
663	of cancer. Generally, HPV16 L1 antibodies are considered cumulative exposure markers,
664	while HPV16 E6 and E7 have been associated with HPV-driven cancers but not all those who
665	test positive are expected to develop a HPV-driven cancer ³⁸ . Summary-level genetic data
666	for HPV16 and HPV18 serological measures were obtained from UK Biobank. We performed
667	individual GWAS for each measure using a similar approach as described by Kachuri <i>et al.</i> ⁶² .
668	Details on how these GWAS were conducted can be found in the Supplementary
669	information.
670	
671	Sensitivity analyses
671 672	Sensitivity analyses The strength of each genetic instrument was determined by the magnitude and precision of
671 672 673	Sensitivity analyses The strength of each genetic instrument was determined by the magnitude and precision of association with the sexual behaviour, which was considered to be sufficient if the
671 672 673 674	Sensitivity analyses The strength of each genetic instrument was determined by the magnitude and precision of association with the sexual behaviour, which was considered to be sufficient if the corresponding F-statistic was >10. The fixed-effect IVW method provides an unbiased
671 672 673 674 675	Sensitivity analyses The strength of each genetic instrument was determined by the magnitude and precision of association with the sexual behaviour, which was considered to be sufficient if the corresponding F-statistic was >10. The fixed-effect IVW method provides an unbiased estimate in the absence of horizontal pleiotropy or when horizontal pleiotropy is balanced
671 672 673 674 675 676	Sensitivity analyses The strength of each genetic instrument was determined by the magnitude and precision of association with the sexual behaviour, which was considered to be sufficient if the corresponding F-statistic was >10. The fixed-effect IVW method provides an unbiased estimate in the absence of horizontal pleiotropy or when horizontal pleiotropy is balanced ³¹ . To account for directional pleiotropy, we compared results with three other MR
 671 672 673 674 675 676 677 	Sensitivity analyses The strength of each genetic instrument was determined by the magnitude and precision of association with the sexual behaviour, which was considered to be sufficient if the corresponding F-statistic was >10. The fixed-effect IVW method provides an unbiased estimate in the absence of horizontal pleiotropy or when horizontal pleiotropy is balanced ³¹ . To account for directional pleiotropy, we compared results with three other MR methods, which each make different assumptions about this: MR-Egger ⁵² , weighted median
 671 672 673 674 675 676 677 678 	Sensitivity analyses The strength of each genetic instrument was determined by the magnitude and precision of association with the sexual behaviour, which was considered to be sufficient if the corresponding F-statistic was >10. The fixed-effect IVW method provides an unbiased estimate in the absence of horizontal pleiotropy or when horizontal pleiotropy is balanced ³¹ . To account for directional pleiotropy, we compared results with three other MR methods, which each make different assumptions about this: MR-Egger ⁵² , weighted median ⁵³ and weighted mode ⁵⁴ . Further detail on these methods is provided in the Supplementary
 671 672 673 674 675 676 677 678 679 	Sensitivity analyses The strength of each genetic instrument was determined by the magnitude and precision of association with the sexual behaviour, which was considered to be sufficient if the corresponding F-statistic was >10. The fixed-effect IVW method provides an unbiased estimate in the absence of horizontal pleiotropy or when horizontal pleiotropy is balanced ³¹ . To account for directional pleiotropy, we compared results with three other MR methods, which each make different assumptions about this: MR-Egger ⁵² , weighted median ⁵³ and weighted mode ⁵⁴ . Further detail on these methods is provided in the Supplementary information (see "Methods") .

681 Positive and negative control analyses

682	To further assess the specificity and sensitivity of the genetic instruments identified in
683	relation to sexual behaviour, we conducted additional positive and negative control MR
684	analyses. These aimed to appraise the role of AFS and NSP on a) cervical cancer and C.
685	trachomatis seropositivity, as positive control outcomes where evidence of an effect would
686	support the aetiological link via HPV; and b) lung cancer and oral cancer as negative
687	controls, where a direct causal effect of sexual behaviour is unlikely and so where any
688	evidence of an effect would indicate potential violation of the MR assumptions due to
689	pleiotropy, population stratification or selection bias ⁶³ . Details on the GWAS summary data
690	used to conduct positive and negative control outcomes can be found in the Supplementary
691	information.
692	
693	Causal Analysis using Summary Effect estimates (CAUSE)
694	While sensitivity analyses like MR-Egger, weighted median and weighted mode can detect
695	horizontal or uncorrelated pleiotropy, whereby the genetic variant affects the exposure
696	(sexual behaviours) and outcome (oropharyngeal cancer) through separate mechanisms,
697	correlated pleiotropy is an alternative scenario which could generate spurious associations
698	in MR. Here, the genetic variant affects the exposure and outcome via a shared heritable
699	factor. Correlated pleiotropy may be present in the genetic instruments for AFS and NSP,
700	

701







704 Fig.4 A. Genetic variants (Z) act as proxies or instruments to investigate if an exposure (X), is 705 associated with a disease outcome (Y). Causal inference can be made between X and Y if the 706 following conditions are upheld: (1) Z is a valid instrument, reliably associated with X 707 ('relevance'); (2) Z is independent of any measured or unmeasured confounding factors (U) 708 ('exchangeability') and (3) there is no independent association between Z and Y except 709 through X ('exclusion restriction'). B. Directed acyclic graph (DAG) depicting correlated 710 pleiotropy (C) whereby the genetic variant (Z) can affect the exposure (X) and the outcome 711 (Y) via a shared heritable factor (C), for example here through smoking, alcohol, or general 712 risk tolerance.

713

714 We used the CAUSE method in an attempt to identify potential correlated pleiotropy ²⁹.

715 CAUSE proposes that any causal effect of an exposure on the outcome leads to correlation

716	for all variants with a non-zero effect on the exposure, while a shared factor induces
717	correlation for only a subset of exposure effect variants ²⁹ . GWAS summary statistics were
718	used to generate two models nested in a "null" effects model. The sharing model allows for
719	horizontal pleiotropic effects but no causal effect (γ = 0), whereas the causal model has γ as
720	a free parameter. The Bayesian expected log pointwise posterior density (ELPD) is used to
721	compare models, producing a one-sided <i>p</i> value which tests the best fitting model. In
722	particular, if the hypothesis that the sharing model fits the data at least as well as the causal
723	model is rejected, we can conclude that the data are consistent with a causal effect 29 .
724	
725	LD Score regression
726	Genetic correlation was calculated between the two sexual behaviour traits (AFS and NSP),
727	smoking, alcohol, and general risk tolerance. Summary-level genome-wide association
728	studies were obtained for alcohol consumption (drinks per week, <i>n=</i> 941,280) and smoking
729	initiation (a binary phenotype indicating whether an individual had ever smoked regularly)
730	(n= 1,232,091) from the GSCAN meta-analysis ³⁵ . Summary statistics were also obtained
731	from a GWAS of general risk tolerance (n=1939,908), derived from a meta-analysis of UK
732	Biobank (n=12431,126) question <i>"Would you describe yourself as someone who takes risks?"</i>
733	and 23andMe (n=12508,782) question <i>"Overall, do you feel comfortable or uncomfortable</i>
734	taking risks?". The GWAS of risk tolerance was based on one's tendency or willingness to
735	take risks, making them more likely to engage in risk-taking behaviours more generally 26 .
736	The regression was performed using pre-computed LD scores calculated based on
737	individuals of European ancestry from 1000 Genomes European data and are appropriate
738	for use with European-ancestry GWAS data 64 . This was filtered to HapMap3 SNPs as these
739	are well-imputed in most studies 65 . SNPs found on chromosome 6 in the region 26MB to

740 34MB were excluded. GWAS summary statistics were converted for LD score regression

- using the munge_sumstats.py command from the command line tool "ldsc", and LD score
- regression was performed using the ldsc.py command.
- 743
- 744 Multivariable Mendelian randomization

745 To account for the potential genetic overlap with other risk factors ²⁰ for oronharynge				20	
	745	To account for the potential	genetic overlap with	n other risk factors 🕫 f	or oropharyngea

- cancer which may lead to correlated pleiotropy, we next conducted two-sample
- 747 multivariable MR analysis. This accounted for the effects of the other sexual behaviour,
- smoking, alcohol consumption and risk tolerance in the MR of each sexual behaviour onto
- the cancer outcomes. First multivariable MR was carried out to assess the effect of genetic
- overlap between AFS and NSP using the genome-wide significant SNPs identified as

instruments in the univariable analysis (272 SNPs for AFS and 117 SNPs for NSP). 196

- independent SNPs ($p < 5 \times 10^{-8}$) were used in the analysis for smoking initiation, 60 SNPs for
- alcoholic drinks per week and 123 for risk tolerance, after excluding SNPs with a pairwise r²
- > 0.001. To better capture lifetime smoking (duration, heaviness, and cessation), we used

108 SNPs which make up the comprehensive smoking index, derived by Wootton et al in the

- 756 UK Biobank (n= 462,690)³⁴. SNP overlap was assessed between all instruments. We used
- 757 generalised versions of Cochran's Q statistical tests for both instrument strength and validity
- ⁶⁶. Both the IVW and MR-Egger framework have been extended to estimate causal effects in
- 759 multivariable MR analysis ^{67,68}, which was conducted using both the MVMR (version 0.2.0)

760 and MendelianRandomization ⁶⁹ (version 0.5.0) packages in R (version 4.0.2).

761

Causal Analysis using Summary Effect Estimates, LD Score Regression and Multivariable
 Mendelian randomization approaches all require full GWAS summary data for the proposed

764	risk factors of interested. Where full data were available for the GWAS of NSP ²⁶ , these have
765	yet to be published for the GWAS of AFS, which we used to select genetic instruments .
766	Therefore, for these approaches, we used another GWAS for AFS, also conducted using UK
767	Biobank data (n=406,457), for which full summary data are publicly available
768	(https://gwas.mrcieu.ac.uk/datasets/ukb-b-6591/). This GWAS was conducted using the
769	MRC IEU UK Biobank GWAS pipeline, more details of which can be found in Elsworth et al,
770	2019 ⁷⁰ .

771

772 Acknowledgements

773 M.G. was a National Institute for Health Research (NIHR) academic clinical fellow and is 774 currently supported by a Wellcome Trust GW4-Clinical Academic Training PhD Fellowship. 775 This research was funded in part, by the Wellcome Trust [Grant number 220530/Z/20/Z]. 776 For the purpose of open access, the author has applied a CC BY public copyright licence to 777 any Author Accepted Manuscript version arising from this submission. R.C.R. is a de Pass VC 778 research fellow at the University of Bristol. J.T. is supported by an Academy of Medical 779 Sciences (AMS) Springboard award, which is supported by the AMS, the Wellcome Trust, 780 Global Challenges Research Fund (GCRF), the Government Department of Business, Energy 781 and Industrial strategy, the British Heart Foundation and Diabetes UK (SBF004\1079). 782 R.M.M. was supported by a Cancer Research UK (C18281/A20919) programme grant (the 783 Integrative Cancer Epidemiology Programme). R.M.M. and A.R.N. are supported by the 784 National Institute for Health Research (NIHR) Bristol Biomedical Research Centre which is 785 funded by the National Institute for Health Research (NIHR) and is a partnership between 786 University Hospitals Bristol NHS Foundation Trust and the University of Bristol. Department

787 of Health and Social Care disclaimer: The views expressed are those of the authors and not 788 necessarily those of the NHS, the NIHR or the Department of Health and Social Care. This 789 publication presents data from the Head and Neck 5000 study. The study was a component 790 of independent research funded by the National Institute for Health Research (NIHR) under 791 its Programme Grants for Applied Research scheme (RP-PG-0707-10034). The views 792 expressed in this publication are those of the author(s) and not necessarily those of the 793 NHS, the NIHR or the Department of Health. Core funding was also provided through awards 794 from Above and Beyond, University Hospitals Bristol and Weston Research Capability 795 Funding and the NIHR Senior Investigator award to A.R.N. Human papillomavirus (HPV) 796 serology was supported by a Cancer Research UK Programme Grant, the Integrative Cancer 797 Epidemiology Programme (C18281/A20919). B.D. and the University of Pittsburgh head and 798 neck cancer case-control study are supported by US National Institutes of Health (NIH) 799 grants: P50 CA097190, P30 CA047904 and R01 DE025712. The genotyping of the HNSCC 800 cases and controls was performed at the Center for Inherited Disease Research (CIDR) and 801 funded by the US National Institute of Dental and Craniofacial Research (NIDCR; 802 1X01HG007780-0). The University of North Carolina (UNC) CHANCE study was supported in 803 part by the National Cancer Institute (R01-CA90731). E.E.V is supported by Diabetes UK 804 (17/0005587). E.E.V is also supported by the World Cancer Research Fund (WCRF UK), as 805 part of the World Cancer Research Fund International grant programme (IIG 2019 2009). 806 E.H.T and P.S. were supported by FAPESP grant 10/51168-0 (GENCAPO/Head and Neck 807 Genome project). M.G., T.D., K.B., A.C., R.M.M., M.M., G.D.S, E.E.V. and R.C.R are part of the 808 Medical Research Council Integrative Epidemiology Unit at the University of Bristol supported by the Medical Research Council (MC UU 00011/1, MC UU 00011/5, 809 810 MC UU 00011/6, MC UU 00011/7).

811

812 **Competing Interests**

The authors declare no conflicts of interest. The funders had no role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript for publication. The authors alone are responsible for the views expressed in this article.

817

818 Author Contributions

819 M.G. and R.C.R. conceived the study and M.G. carried out data curation and analysis, 820 validating the results separately. L.K. completed both the HPV and cervical cancer GWAS 821 and helped with interpretation of these data. T.W. and N.B. produced serology data for HPV 822 in the UK Biobank pilot and provided expertise on interpretation of these data. Head and 823 neck cancer summary genetic data was obtained through multiple collaborations from 824 studies lead by A.R.N., S.T., A.F.O., R.J.H., G.L., B.D., S.B., E.T., P.S., T.N.T., M.L. and P.B. The 825 initial manuscript was drafted by M.G., L.K., G.D.S. and R.C.R. Expert guidance on MR 826 methodology was provided by L.K., T.D., K.B., B.D., R.C.R., G.D.S, R.M.M. All authors M.G., 827 T.D., L.K., K.B., A.C., R.M.M., S.T., J.T., A.R.N., P.B., M.M., M.P., S.B., A.F.O., B.D., R.J.H., G.L., 828 E.T., P.S., T.N.T., M.L., T.W., N.B., G.D.S., E.V. and R.C.R. contributed to the interpretation of 829 the results and critical revision of the manuscript. M.G. supervisory team includes R.C.R., 830 E.V., J.T., A.R.N and G.D.S.

831

832 Data availability

833

- 834 Summary-level analysis was conducted using publicly available GWAS data. Full summary
- statistics for the GAME-ON GWAS can be accessed via dbGAP (OncoArray: Oral and Pharynx
- 836 Cancer; study accession number: phs001202.v1.p1) and via the IEU OpenGWAS
- 837 project https://gwas.mrcieu.ac.uk/. Access to UK Biobank (https://www.ukbiobank.ac.uk/.
- 838 data is available to researchers through application. For the purpose of open access, the
- 839 author has applied a CC BY public copyright licence to any Author Accepted Manuscript
- 840 version arising from this submission. UK Biobank approval was given for this project (ID
- 841 40644 "Investigating aetiology, associations and causality in diseases of the head and neck")
- and UK Biobank GWAS data was also accessed under the application (ID 15825 "MR-Base:
- an online resource for Mendelian randomization using summary data"- Dr Philip Haycock)."

844

845 **Code availability statement**

- 846
- 847 MR analyses were conducted using the "TwoSampleMR" package in R (version 3.5.3). A copy
- 848 of the code and all files used in this analysis is available at:
- 849 <u>https://github.com/rcrichmond/sexual_behaviours_opc</u>
- 850
- 851
- 852
- 853
- 854

855

856 **References**

857

- 8581Thomas, S. J., Penfold, C. M., Waylen, A. & Ness, A. R. The changing aetiology of head859and neck squamous cell cancer: A tale of three cancers? *Clin Otolaryngol* **43**, 999-
- 860 1003 (2018).
- 861 2 Sung, H. *et al.* Global cancer statistics 2020: GLOBOCAN estimates of incidence and
- 862 mortality worldwide for 36 cancers in 185 countries. *CA: A Cancer Journal for*
- 863 *Clinicians* (2021).
- Syrjanen, K., Syrjanen, S., Lamberg, M., Pyrhonen, S. & Nuutinen, J. Morphological
- 865 and immunohistochemical evidence suggesting human papillomavirus (HPV)
- 866 involvement in oral squamous cell carcinogenesis. *Int J Oral Surg* **12**, 418-424 (1983).
- 867 4 Smith, E. M. *et al.* Human papillomavirus seropositivity and risks of head and neck
- 868 cancer. Int J Cancer **120**, 825-832 (2007).
- 5 D'Souza, G. *et al.* Case-control study of human papillomavirus and oropharyngeal
- 870 cancer. *New Engl J Med* **356**, 1944-1956 (2007).
- 871 6 Pan, C., Issaeva, N. & Yarbrough, W. G. HPV-driven oropharyngeal cancer: current
- 872 knowledge of molecular biology and mechanisms of carcinogenesis. *Cancers Head*
- 873 Neck **3**, 12 (2018).
- 874 7 Chaturvedi, A. K. *et al.* Worldwide Trends in Incidence Rates for Oral Cavity and
- 875 Oropharyngeal Cancers. *Journal of Clinical Oncology* **31**, 4550-4559 (2013).
- 876 8 Gillison, M. L. *et al.* Evidence for a causal association between human papillomavirus
- and a subset of head and neck cancers. J Natl Cancer Inst 92, 709-720 (2000).

878	9	Gillison, M. L.	Chaturvedi, A. K	., Anderson, W. F	. & Fakhrv	. C. Epidemiology of
	-			,		,

- 879 Human Papillomavirus-Positive Head and Neck Squamous Cell Carcinoma. *J Clin*
- 880 Oncol **33**, 3235-3242 (2015).
- 881 10 Castellsagué, X. et al. HPV Involvement in Head and Neck Cancers: Comprehensive
- Assessment of Biomarkers in 3680 Patients. *J Natl Cancer Inst* **108**, djv403 (2016).
- 883 11 Kreimer, A. R. et al. Evaluation of human papillomavirus antibodies and risk of
- subsequent head and neck cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* **31**, 2708-2715 (2013).
- 886 12 Kreimer, A. R. *et al.* Kinetics of the Human Papillomavirus Type 16 E6 Antibody
- 887 Response Prior to Oropharyngeal Cancer. *JNCI: Journal of the National Cancer*
- 888 Institute **109** (2017).
- Anantharaman, D. *et al.* Human papillomavirus infections and upper aero-digestive
 tract cancers: the ARCAGE study. *J Natl Cancer Inst* **105**, 536-545 (2013).
- 891 14 Ribeiro, K. B. *et al.* Low human papillomavirus prevalence in head and neck cancer:
- 892 results from two large case-control studies in high-incidence regions. Int J Epidemiol
- **40**, 489-502 (2011).
- 15 Heck, J. E. *et al.* Sexual behaviours and the risk of head and neck cancers: a pooled
- analysis in the International Head and Neck Cancer Epidemiology (INHANCE)
- 896 consortium. *Int J Epidemiol* **39**, 166-181 (2010).
- 897 16 Herrero, R. *et al.* Human papillomavirus and oral cancer: the International Agency for
- 898 Research on Cancer multicenter study. *J Natl Cancer Inst* **95**, 1772-1783 (2003).
- 899 17 Schwartz, S. M. *et al.* Oral cancer risk in relation to sexual history and evidence of
- 900 human papillomavirus infection. *J Natl Cancer Inst* **90**, 1626-1636 (1998).

- 901 18 Rajkumar, T. et al. Oral cancer in Southern India: the influence of body size, diet,
- 902 infections and sexual practices. *Eur J Cancer Prev* **12**, 135-143 (2003).
- 903 19 Smith, E. M. *et al.* Age, sexual behavior and human papillomavirus infection in oral
- 904 cavity and oropharyngeal cancers. *Int J Cancer* **108**, 766-772 (2004).
- 905 20 Shah, A. *et al.* Oral sex and human papilloma virus-related head and neck squamous
- 906 cell cancer: a review of the literature. *Postgrad Med J* **93**, 704-709 (2017).
- 907 21 Doorbar, J. & Griffin, H. Refining our understanding of cervical neoplasia and its
- 908 cellular origins. *Papillomavirus Res* **7**, 176-179 (2019).
- 909 22 Farsi, N. J. *et al.* Sexual behaviours and head and neck cancer: A systematic review
- 910 and meta-analysis. *Cancer Epidemiol* **39**, 1036-1046 (2015).
- 911 23 Khadr, S. N. et al. Investigating the relationship between substance use and sexual
- 912 behaviour in young people in Britain: findings from a national probability survey.
- 913 BMJ Open 6, e011961 (2016).
- 914 24 Davey Smith, G. & Hemani, G. Mendelian randomization: genetic anchors for causal
- 915 inference in epidemiological studies. *Hum Mol Genet* **23**, R89-98 (2014).
- 916 25 Smith, G. D. & Ebrahim, S. 'Mendelian randomization': can genetic epidemiology
- 917 contribute to understanding environmental determinants of disease? Int J Epidemiol
- 918 **32**, 1-22 (2003).
- 919 26 Karlsson Linner, R. et al. Genome-wide association analyses of risk tolerance and
- 920 risky behaviors in over 1 million individuals identify hundreds of loci and shared
- 921 genetic influences. *Nat Genet* **51**, 245-257 (2019).
- 922 27 Ganna, A. *et al.* Large-scale GWAS reveals insights into the genetic architecture of 923 same-sex sexual behavior. *Science* **365**, eaat7693 (2019).

- 924 28 Mills, M. C. et al. Identification of 370 loci for age at onset of sexual and reproductive
- 925 behaviour, highlighting common aetiology with reproductive biology, externalizing
- 926 behaviour and longevity. *bioRxiv*, 2020.2005.2006.081273 (2020).
- 927 29 Morrison, J., Knoblauch, N., Marcus, J. H., Stephens, M. & He, X. Mendelian
- 928 randomization accounting for correlated and uncorrelated pleiotropic effects using
- genome-wide summary statistics. *Nat Genet* (2020).
- 930 30 Bowden, J. et al. Assessing the suitability of summary data for two-sample
- 931 Mendelian randomization analyses using MR-Egger regression: the role of the I2
- 932 statistic. Int J Epidemiol **45**, 1961-1974 (2016).
- 933 31 Hemani, G., Bowden, J. & Smith, G. D. Evaluating the potential role of pleiotropy in
- 934 Mendelian randomization studies. *Hum Mol Genet* 27, R195-R208 (2018).
- 935 32 Morrison, J., Knoblauch, N., Marcus, J. H., Stephens, M. & He, X. Mendelian
- 936 randomization accounting for correlated and uncorrelated pleiotropic effects using

genome-wide summary statistics. *Nat Genet* **52**, 740-747 (2020).

- 938 33 Elsworth, B. et al. The MRC IEU OpenGWAS data infrastructure. bioRxiv,
- 939 2020.2008.2010.244293 (2020).
- 940 34 Wootton, R. E. *et al.* Evidence for causal effects of lifetime smoking on risk for

941 depression and schizophrenia: a Mendelian randomisation study. *Psychol Med*, 1-9
942 (2019).

- 943 35 Liu, M. Z. *et al.* Association studies of up to 1.2 million individuals yield new insights
- 944 into the genetic etiology of tobacco and alcohol use. *Nat Genet* **51**, 237-+ (2019).
- 945 36 Pan, C., Issaeva, N. & Yarbrough, W. G. HPV-driven oropharyngeal cancer: current
- 946 knowledge of molecular biology and mechanisms of carcinogenesis. *Cancers of the*
- 947 *Head & Neck* **3**, 12 (2018).

948	37	Chung, C. H. & Gillison, M. L. Human Papillomavirus in Head and Neck Cancer: Its
949		Role in Pathogenesis and Clinical Implications. Clinical Cancer Research 15, 6758-
950		6762 (2009).
951	38	Brenner, N. et al. Characterization of human papillomavirus (HPV) 16 E6 seropositive
952		individuals without HPV-associated malignancies after 10 years of follow-up in the
953		UK Biobank. <i>EBioMedicine</i> 62 , 103123 (2020).
954	39	Mentzer, A. J. et al. Identification of host-pathogen-disease relationships using a
955		scalable Multiplex Serology platform in UK Biobank. <i>medRxiv</i> , 19004960 (2019).
956	40	Dahlstrom, K. R. et al. HPV Serum Antibodies as Predictors of Survival and Disease
957		Progression in Patients with HPV-Positive Squamous Cell Carcinoma of the
958		Oropharynx. Clinical cancer research : an official journal of the American Association
959		for Cancer Research 21 , 2861-2869 (2015).
960	41	Perdomo, S., Martin Roa, G., Brennan, P., Forman, D. & Sierra, M. S. Head and neck
961		cancer burden and preventive measures in Central and South America. <i>Cancer</i>
962		Epidemiology 44 , S43-S52 (2016).
963	42	Kreimer, A. R., Clifford, G. M., Boyle, P. & Franceschi, S. Human papillomavirus types
964		in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer
965		Epidemiol Biomarkers Prev 14 , 467-475 (2005).
966	43	Dayyani, F. <i>et al.</i> Meta-analysis of the impact of human papillomavirus (HPV) on
967		cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC).
968		Head Neck Oncol 2 , 15 (2010).
969	44	Gayet, C., Juarez, F. & Bozon, M. Vol. 5 67-90 (2013).
970	45	Bosetti, C. et al. Global trends in oral and pharyngeal cancer incidence and mortality.
971		Int J Cancer 147 , 1040-1049 (2020).

972	46	Schache, A. G. et al. HPV-Related Oropharynx Cancer in the United Kingdom: An
973		Evolution in the Understanding of Disease Etiology. <i>Cancer Res</i> 76, 6598-6606
974		(2016).
975	47	Kreimer, A. R. et al. Incidence and clearance of oral human papillomavirus infection
976		in men: the HIM cohort study. Lancet (London, England) 382 , 877-887 (2013).
977	48	Castle, P. E. How does tobacco smoke contribute to cervical carcinogenesis? J Virol
978		82 , 6084-6086 (2008).
979	49	Arnson, Y., Shoenfeld, Y. & Amital, H. Effects of tobacco smoke on immunity,
980		inflammation and autoimmunity. <i>J Autoimmun</i> 34 , J258-265 (2010).
981	50	Hashibe, M. et al. Interaction between Tobacco and Alcohol Use and the Risk of
982		Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer
983		Epidemiology Consortium. <i>Cancer Epidem Biomar</i> 18, 541-550 (2009).
984	51	Gormley, M. et al. A multivariable Mendelian randomization analysis investigating
985		smoking and alcohol consumption in oral and oropharyngeal cancer. Nat Commun
986		11 , 6071 (2020).
987	52	Bowden, J., Davey Smith, G. & Burgess, S. Mendelian randomization with invalid
988		instruments: effect estimation and bias detection through Egger regression. Int J
989		Epidemiol 44 , 512-525 (2015).
990	53	Bowden, J., Smith, G. D., Haycock, P. C. & Burgess, S. Consistent Estimation in
991		Mendelian Randomization with Some Invalid Instruments Using a Weighted Median
992		Estimator. <i>Genet Epidemiol</i> 40 , 304-314 (2016).
993	54	Hartwig, F. P., Smith, G. D. & Bowden, J. Robust inference in summary data
994		Mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol
995		46 , 1985-1998 (2017).

- 996 55 Mounier, N. & Kutalik, Z. Correction for sample overlap, winner's curse and weak
- 997 instrument bias in two-sample Mendelian Randomization. *bioRxiv*,
- 998 2021.2003.2026.437168 (2021).
- 999 56 Minelli, C. et al. The use of two-sample methods for Mendelian randomization
- 1000 analyses on single large datasets. *bioRxiv*, 2020.2005.2007.082206 (2020).
- 1001 57 Lawlor, D. A., Tilling, K. & Davey Smith, G. Triangulation in aetiological epidemiology.
- 1002 *Int J Epidemiol* **45**, 1866-1886 (2017).
- 1003 58 Munafo, M. R. & Davey Smith, G. Robust research needs many lines of evidence.
- 1004 *Nature* **553**, 399-401 (2018).
- 1005 59 Demange, P. A. *et al.* Investigating the genetic architecture of noncognitive skills

1006 using GWAS-by-subtraction. *Nat Genet* **53**, 35-44 (2021).

1007 60 Lesseur, C. *et al.* Genome-wide association analyses identify new susceptibility loci

1008 for oral cavity and pharyngeal cancer. *Nat Genet* **48**, 1544-1550 (2016).

- 1009 61 Dudding, T. *et al.* Assessing the causal association between 25-hydroxyvitamin D and
- 1010 the risk of oral and oropharyngeal cancer using Mendelian randomization. Int J
- 1011 *Cancer* **143**, 1029-1036 (2018).
- 1012 62 Kachuri, L. *et al.* The landscape of host genetic factors involved in immune response

1013 to common viral infections. *Genome Medicine* **12**, 93 (2020).

- 1014 63 Sanderson, E., Richardson, T. G., Hemani, G. & Davey Smith, G. The use of negative
- 1015 control outcomes in Mendelian randomization to detect potential population
- 1016 stratification. *Int J Epidemiol* (2021).
- 1017 64 Auton, A. *et al.* A global reference for human genetic variation. *Nature* **526**, 68-74

1018 (2015).

- 1019 65 Altshuler, D. M. *et al.* Integrating common and rare genetic variation in diverse
- 1020 human populations. *Nature* **467**, 52-58 (2010).
- 1021 66 Sanderson, E., Davey Smith, G., Windmeijer, F. & Bowden, J. An examination of
- 1022 multivariable Mendelian randomization in the single-sample and two-sample
- summary data settings. Int J Epidemiol (2018).
- 1024 67 Rees, J. M. B., Wood, A. M. & Burgess, S. Extending the MR-Egger method for
- 1025 multivariable Mendelian randomization to correct for both measured and
- 1026 unmeasured pleiotropy. *Stat Med* **36**, 4705-4718 (2017).
- 1027 68 Burgess, S., Dudbridge, F. & Thompson, S. G. Re: "Multivariable Mendelian
- 1028 randomization: the use of pleiotropic genetic variants to estimate causal effects".
- 1029 *Am J Epidemiol* **181**, 290-291 (2015).
- 1030 69 Yavorska, O. O. & Burgess, S. MendelianRandomization: an R package for performing
- 1031 Mendelian randomization analyses using summarized data. Int J Epidemiol 46, 1734-
- 1032 1739 (2017).
- 1033 70 Mitchell, R., Elsworth, BL, Mitchell, R, Raistrick, CA, Paternoster, L, Hemani, G, Gaunt,
- 1034 TR. (2019).